AMCON Distributing Co. (DIT) EPS Estimated At $0.00; Cerulean Pharma (CERU) Sellers Decreased By 4.29% Their Shorts

June 29, 2017 - By Dolores Ford

Cerulean Pharma Incorporated (NASDAQ:CERU) had a decrease of 4.29% in short interest. CERU’s SI was 2.61M shares in June as released by FINRA. Its down 4.29% from 2.73 million shares previously. With 1.05 million avg volume, 3 days are for Cerulean Pharma Incorporated (NASDAQ:CERU)’s short sellers to cover CERU’s short positions. The SI to Cerulean Pharma Incorporated’s float is 18.15%. The stock increased 3.76% or $0.016 during the last trading session, reaching $0.43. About shares traded. Cerulean Pharma Inc (NASDAQ:CERU) has declined 82.21% since June 29, 2016 and is downtrending. It has underperformed by 98.91% the S&P500.

Analysts expect AMCON Distributing Co. (NYSEMKT:DIT) to report $0.00 EPS on July, 17. It closed at $105.5 lastly. It is down 33.62% since June 29, 2016 and is uptrending. It has outperformed by 16.92% the S&P500.

Investors sentiment decreased to 2.4 in Q4 2016. Its down 1.60, from 4 in 2016Q3. It fall, as 2 investors sold AMCON Distributing Co. shares while 3 reduced holdings. 4 funds opened positions while 8 raised stakes. 84,857 shares or 47.29% less from 160,988 shares in 2016Q3 were reported. Deutsche Natl Bank Ag owns 1 shares for 0% of their portfolio. James Inv Research invested 0% in AMCON Distributing Co. (NYSEMKT:DIT). Denali Ltd Liability holds 0% or 25 shares. Grt Capital Partners Ltd Liability reported 1,779 shares or 0.06% of all its holdings. Morgan Stanley has 430 shares for 0% of their portfolio. Moreover, Royal Bancorp Of Canada has 0% invested in AMCON Distributing Co. (NYSEMKT:DIT). Federated Investors Inc Pa invested in 19 shares. Lsv Asset Management reported 9,211 shares stake. Blackrock Fund Advisors invested in 53 shares. Nationwide Fund Advsrs holds 1,300 shares. Wells Fargo And Mn reported 1 shares or 0% of all its holdings. Vanguard Gp Inc reported 7,310 shares. Blackrock Inv Limited Liability Com owns 60 shares. Acadian Asset Management Limited owns 195 shares for 0% of their portfolio. Bridgeway Cap Mgmt stated it has 0.01% of its portfolio in AMCON Distributing Co. (NYSEMKT:DIT).

AMCON Distributing Company and its subsidiaries are engaged in the wholesale distribution of consumer products in the Central, Rocky Mountain, and Southern regions of the United States. The company has market cap of $71.29 million. The Firm has two divisions: wholesale distribution segment (Wholesale segment) and retail health food segment (Retail Segment). It has a 14.76 P/E ratio. The Wholesale Segment offers retailers the ability to utilize manufacturer- and Company-sponsored sales and marketing programs, merchandising and product category management services.

Among 7 analysts covering Cerulean Pharmaceuticals (NASDAQ:CERU), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Cerulean Pharmaceuticals had 12 analyst reports since August 7, 2015 according to SRatingsIntel. TH Capital initiated it with “Buy” rating and $9.0 target in Friday, August 28 report. Barclays Capital maintained Cerulean Pharma Inc (NASDAQ:CERU) rating on Tuesday, August 30. Barclays Capital has “Overweight” rating and $2 target. Roth Capital initiated Cerulean Pharma Inc (NASDAQ:CERU) on Friday, August 28 with “Buy” rating. As per Wednesday, March 9, the company rating was maintained by JMP Securities. Barclays Capital initiated Cerulean Pharma Inc (NASDAQ:CERU) on Tuesday, September 22 with “Overweight” rating. The firm earned “Market Perform” rating on Thursday, August 18 by JMP Securities. The stock of Cerulean Pharma Inc (NASDAQ:CERU) has “Neutral” rating given on Thursday, August 18 by Wedbush. On Thursday, August 18 the stock rating was downgraded by Leerink Swann to “Market Perform”. The rating was initiated by Janney Capital on Wednesday, January 6 with “Buy”. The firm has “Neutral” rating by Janney Capital given on Thursday, August 18.

Cerulean Pharma Inc. is a clinical-stage, oncology-focused company. The company has market cap of $12.01 million. The Firm applies its Dynamic Tumor Targeting platform to develop differentiated therapies. It currently has negative earnings. The Company’s platform utilizes nanoparticle-drug conjugates , which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.

Investors sentiment increased to 1.33 in Q4 2016. Its up 0.77, from 0.56 in 2016Q3. It improved, as 5 investors sold Cerulean Pharma Inc shares while 4 reduced holdings. 5 funds opened positions while 7 raised stakes. 5.25 million shares or 16.37% less from 6.28 million shares in 2016Q3 were reported. Royal National Bank & Trust Of Canada reported 0% of its portfolio in Cerulean Pharma Inc (NASDAQ:CERU). Northeast Fin Consultants Inc stated it has 20,000 shares or 0.01% of all its holdings. Renaissance Ltd Llc stated it has 0% in Cerulean Pharma Inc (NASDAQ:CERU). Oxford Asset Management, a United Kingdom-based fund reported 40,656 shares. Northern reported 13,066 shares. Reilly Fincl Limited Liability Company has invested 0% in Cerulean Pharma Inc (NASDAQ:CERU). Commercial Bank Of Montreal Can reported 0% in Cerulean Pharma Inc (NASDAQ:CERU). Brown Advisory holds 0% or 30,000 shares. Rock Springs Management Ltd Partnership holds 625,000 shares. Minnesota-based Walleye Trading has invested 0% in Cerulean Pharma Inc (NASDAQ:CERU). 33,883 were reported by Goldman Sachs Grp Inc Inc. Creative Planning reported 0% of its portfolio in Cerulean Pharma Inc (NASDAQ:CERU). State Bank Of America De holds 7,000 shares or 0% of its portfolio. Polaris Venture Mgmt V stated it has 3.29 million shares. Morgan Stanley has 24,058 shares.